Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2026—Though it may test the memory of many, there once was a time when HER2 immunohistochemistry was a relatively uncomplicated matter. Back in September 1998, the FDA approved both trastuzumab (Herceptin) and the first companion diagnostic assay, HercepTest, which was used to determine whether patients with metastatic breast cancer could receive the new drug.
September 2026—Amyloidosis has become a treatable disease—if the fibril type is identified accurately and quickly. That and the variability seen in its workup and diagnosis were the impetus for the recently published CAP amyloidosis guideline. The co-chairs of the guideline expert panel provided, in a CAP25 session, what they described as their own tips and tricks for amyloid detection and fibril typing, reported here.
September 2026—Technology and regulation have always co-evolved, and artificial intelligence should be no exception. “The tech industry would have Americans believe there should be no regulation of anything that has AI in its title until such time as the technology is fully matured and ready to be regulated,” says Brian R. Jackson, MD, MS, professor of pathology, director of clinical pathology, and CLIA director of laboratories, University of Maryland Medical Center. He calls it “complete gaslighting.”
September 2026—What do leaders of the Digital Pathology Association have to say about where digital pathology stands now and what to expect from AI? Six DPA leaders met online July 24 with CAP TODAY publisher Bob McGonnagle to talk about the technology and the tools. Many patients still don’t understand pathology’s role, said Orly Ardon, PhD, MBA, of Memorial Sloan Kettering Cancer Center, “and AI can create additional concerns if it is not explained properly.”
September 2026—As transitions to a digital pathology workflow grow in number, the question may become less about the extent to which digital slide assessment will be used in practice and more about how to work with those slides. While scanners, image management systems, and storage are most talked about, among other things, researchers at Western University in London, Ontario, turned their attention to the interface itself. They studied whether eye- and head-tracking technologies can serve as alternative input devices to hand-based input devices for digital pathology tasks.
August 2026—Testing for homologous recombination deficiency (HRD) is not for the faint of heart. Even the experts agree. Tricia Numan, MD, says that when she first became involved in the topic, “I didn’t realize how many components went into HRD testing,” including germline alterations, somatic alterations, and various classifications of genomic instability.
August 2026—Recognizing and reporting histologic subtypes and divergent differentiation in urothelial carcinoma is critical for diagnosis, prognosis, and treatment. “Ideally, you want to mention the subtype histologies in pathology reports and quantify the amount,” said Francesca Khani, MD, associate professor in the Department of Pathology and Laboratory Medicine and in the Department of Urology, Weill Cornell Medicine. In a CAP25 session last fall, Dr. Khani spoke of the mimics of benign entities and of other malignancies.
August 2026—A series of hands-on or role-playing workshops created by pathology student interest group leaders at a California medical school introduced pathology to dozens of students who would have otherwise completed their curriculum without that exposure.
July 2026—When Neha Gupta, MD, attended a fellowship fair early in her second year of residency, she was caught off guard by the number of programs already accepting applications from her peers. It was only March, and she had been told she could apply for her fellowship in late summer.
July 2026—An International Association for the Study of Lung Cancer panel provided recommendations in 2020 on how to process lung cancer resection specimens and define pathologic response after neoadjuvant therapy. They were intended as guidance for clinical trials but offered as a suggestion for good clinical practice.
